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The field of biogerontology and regenerative medicine 
is rapidly evolving with many new advances in aging 
research promising to transform healthcare and extend 
healthy productive longevity. Recent breakthroughs in 
epigenetic, transcriptomic and multimodal biomarkers 
of aging, discovery of new and validation of old 
geroprotectors and advances in gene therapy provide an 
optimistic outlook. However, the propagation of 
laboratory advances into clinical practice has been 
comparatively slow with few focused investment and 
technology integration programs worldwide.  
 
To evaluate the technological readiness of the 
biomedical advances in biogerontology and accelerate 
the translation from laboratory to clinical and 
commercial setting, a community of scientists with 
support from the innovative investment companies 
organized the third bi-annual international conference 
titled "Biomedical Innovation for healthy longevity" in 
Saint-Petersburg, Russia in 25-27 of April 2016. The 
conference was organized by Alexey Moskalev, Alex 
Zhavoronkov, Vladimir Anisimov, Olga Tkacheva 
with support from the Fomenko family including 
Andrei Fomenko, Lada Fomenko and Isabel Fomenko 
acknowledged in this paper and attended by over 400 
scientists from over 20 countries, representing the largest 
biomedical centers and presenting their work. 
 
The conference included two parallel tracks covering 
research and translational aspects of aging research and 
three open round tables on longevity journalism, new 
methods of financing aging research and classifying 
ageing as a disease in the context of International 
Classification of Diseases 11th Revision (ICD-11) 
chaired by Alex Zhavoronkov, Alexey Moskalev and 
Daria Khaltourina with over 30 prominent scientists 
and medical doctors present. While most roundtable 
participants agreed that it is important to classify ageing 
as a disease to attract attention and resources to the field 
and make preventative treatments reimbursable with 
specific codes, there was major disagreements on the 
research, medical, ethical, regulatory and business 
issues. Two main approaches for classifying ageing as a 
disease were considered: assigning ageing a separate 
actionable code and developing a taxonomy of age-
associated conditions with separate codes. The 
roundtable concluded with the proposal to develop an 
open community-managed discussion group using a 
common MediaWiki engine at http://www.ICD-11.org 
to explore the various approaches, aggregate the 
proposals and engage in international collaboration on 
both the ICD-11 and other disease classification 
registries.  
 
Over 60 scientists gave talks, presented posters and 
submitted abstracts for the conference.  
 Brian Kennedy (Buck Institute for Research on Aging, 
USA) presented “Gender-specific effects of the mTOR 
pathway on metabolism and aging”. Claudio 
Franceschi (University of Bologna) reported 
“Decelerated aging in semi-supercentenarians and their 
offspring according to the epigenetic clock”. Andrei V. 
Gudkov (Roswell Park Cancer Institute) presented 
“Origin, biological significance and pharmacological 
targeting of senescent cells in vivo”. Vishwa Deep 
Dixit (Yale School of Medicine) presented 
“Inflammasome and age-related inflammation”. 
  
Igor Kovalchuk (University of Lethbridge) in his 
report “Epigenetics of aging – from mechanisms to 
preventative strategies” presented an epigenetic theory 
of aging and the novel modes of epigenetic anti-aging 
interventions. Cells in the aging body exhibit extensive 
differences to cells in the juvenile organism, ranging 
from changes in gene expression and DNA methylation 
patterns, shortened telomeres, to the deteriorating 
genome maintenance mechanisms. At the tissue, organ 
and systemic level, cells are exposed to the altered 
stromal milieu caused by the altered secretory profiles 
of senescent cells and the deteriorating immune system 
which is not equally able to mount an immune response 
towards new antigens. The combination of these factors 
may facilitate the malignant transformation of cells and 
prevent the efficient recognition and clearance of 
transformed cells, thus leading to cancer predisposition. 
  
Wolfgang Wagner (Helmholtz-Institute for Biomedical 
Engineering) presented “Simple Epigenetic Biomarkers 
for Biological Age”. Aging is reflected by specific 
modifications in the DNA-methylation (DNAm) 
pattern. These epigenetic changes are enriched in 
developmental genes and can be reversed by 
reprogramming into induced pluripotent stem cells 
(iPSCs). Apparently, iPSC-derived cells remain 
epigenetically rejuvenated. Age-associated hyper-
methylation seems to be coherently modified in cancer 
and may reflect chromosomal reorganization that favors 
tumor-initiating genomic mutations. We established a 
simple signature based on DNAm levels at only three 
specific CpG sites (associated with the genes PDE4C, 
ASPA, and ITGA2B). This approach facilitates age 
predictions of blood samples with a mean absolute 
deviation from chronological age (MAD) of less than 
five years. The method is also applicable for buccal 
swabs, which facilitate non-invasive harvesting of 
DNA. However, the models need to be adjusted for this 
different specimen and the precision of age-predictions 
can be increased by using an additional cell-type 
specific signature - a “buccal-cell-signature” - that 
reflect the composition of buccal epithelial cells and 
leucocytes. Notably, there is evidence that simple 
epigenetic signatures can also be indicative for of all-
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cause mortality in later life. These results hold the 
perspective that simple epigenetic biomarkers, based on 
few or individual age-associated CpGs, can assist 
estimation of biological age. 
  
Jan Vijg (Albert Einstein College of Medicine) 
“Genome instability: A conserved mechanism of 
Aging?”. DNA mutations in somatic cells have since 
long been considered as a possible causal contributor to 
aging. However, since somatic mutations are rare they 
can only be detected in clonal lineages, such as tumors 
or organoids. We developed a reliable, validated assay 
to detect mutations across the genome in single cells or 
nuclei after whole genome amplification. Using this 
assay we discovered that mutation frequency in somatic 
cells is much higher than in the germline, confirming 
the disposable nature of the soma. Our results also show 
an age-related increase in somatic DNA mutations in 
human white blood cells. We plan to use the single-cell 
genomics assay to study the landscape of somatic 
mutations in different organs and tissues of aging 
humans.  
  
Yousin Suh (Albert Einstein College of Medicine) 
reported “Functional genomics approach to develop 
targets for slowing aging in humans”. The discovery of 
evolutionarily conserved pathways with major impact on 
lifespan and health span in animal models has suggested 
a potential to identify therapeutic targets for interventions 
that could favorably influence age-related outcomes in 
humans. Identification of gene variants that protect 
humans against crippling diseases at old age is likely to 
help find novel strategies for prevention and therapy. 
With the advent of novel high-throughput genomic 
technologies, discovery of functional pathways that 
influence lifespan or health span in humans is now 
feasible through identification of genetic variants 
associated with these outcomes. Since longevity is 
associated with diminished risk for diseases and 
pathologies, novel potential therapeutic targets could be 
identified based on knowledge of functional pathways of 
gene variants associated with longevity. We have been 
conducting systematic multidisciplinary studies to 
discover functional gene variants associated with 
longevity in the conserved pathways of aging, including 
(epi)genome maintenance, using functional genomics 
approach. To understand molecular mechanisms 
underlying the association with longevity, functional 
consequences of gene variants on age-related parameters 
are assessed in cell culture and in vivo animal models. 
The results may open up the possibility of targeted and 
personalized intervention strategies, ultimately leading to 
improved quality of life of the elderly population. 
  
Guang-Hui Liu (Institute of Biophysics of Chinese 
Academy of Sciences) presented "Using stem cell and 
gene editing techniques to study and treat human 
genetic disorders". Gilford progeria syndrome (HGPS) 
and Werner syndrome (WS) are two human premature 
aging disorders with features that closely recapitulate 
the features of human ageing. Mutations in LMNA and 
WRN genes lead to aberrant splicing product progerin 
and protein loss in HGPS and WS, respectively. Study 
on how genetic alteration leads to the cellular and 
organismal phenotypes of premature aging will provide 
clues to the molecular mechanisms that underlie 
physiological ageing and increase our understanding of 
molecular pathways contributing to healthy aging. We 
have generated induced pluripotent stem cells (iPSCs) 
from fibroblasts obtained from patients with HGPS. 
Further, using targeted gene correction technology, we 
successfully corrected the mutated LMNA gene in 
HGPS-iPSCs. Finally, by using targeted “knock-out” 
and “knock-in” technique, we also created WS-specific 
human embryonic stem cells (hESCs) with WRN 
mutation as well as Parkinson’s disease (PD)-specific 
hESCs with LRRK2 mutation. Upon differentiation of 
these "diseased" human pluripotent stem cells into 
different somatic cell types, they demonstrated aging-
associated tissue-specific disease phenotypes. Together, 
these tools offer unprecedented platforms to study the 
pathogenesis of human aging and aging-related diseases. 
  
Vadim Gladyshev (Harvard Medical School) “Lifespan 
control across species and model systems”. Many 
human diseases are associated with aging, which is 
often their most significant risk factor. The aging 
process can be regulated during evolution, e.g. 
mammals show >100-fold difference in lifespan. We 
employ this diversity to shed light on mechanisms that 
regulate lifespan. For this, we apply comparative 
genomics to short- and long-lived species and carry out 
analyses across panels of mammals. We sequenced the 
genomes of several mammals with exceptional lifespan 
and identified genes that may contribute to their 
longevity. In addition, we carried out analyses of gene 
expression, metabolites and elements across large 
panels of mammals. We also analyzed gene expression 
across different cell types that are characterized by 
different longevity (cell turnover). These studies point 
to both unique (to cells, lineages) and common 
adaptations to longevity involving various pathways. It 
is our hope that a better understanding of molecular 
mechanisms of mammalian lifespan control will lead to 
a better understanding of human diseases of aging. 
 
Andrey Seluanov (University of Rochester) 
“Longevity mechanisms in the naked mole rat and other 
long-lived mammals”. 
  
John Tower (University of Southern California, Los 
Angeles) “Sex-specific regulation of life span in 
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Drosophila”. Aging in Drosophila is associated with up-
regulation of the innate immune response, the oxidative 
stress response, and the proteotoxicity response, 
including the mitochondrial unfolded protein response 
(UPRmt); these changes suggest an aging-associated 
failure in mitochondrial maintenance that limits life 
span.  Accordingly, we found that transgenic reporters 
for genes of innate immune response (antimicrobial 
peptide/AMP genes), cytoplasmic UPR (Hsp70) and 
UPRmt (Hsp22) are predictive biomarkers of life span. 
Mifepristone/RU486 is a glucocorticoid receptor 
antagonist and progesterone receptor antagonist with 
human female contraceptive and abortifacient activities, 
reported to reduce inflammation. In female Drosophila, 
mating increases reproduction and inflammation and 
decreases life span.  We found that mifepristone/RU486 
acts in Drosophila females to decrease reproduction, 
delay inflammation and increase median life span up 
to +68%.  Long-lived females had normal or increased 
food consumption based on dye-uptake and capillary-
feeding assays, arguing against a dietary restriction 
mechanism. Both mating and mifepristone/RU486 
changed median life span by altering initial mortality 
rate.  High-throughput RNA sequencing was used to 
identify genes up-regulated or down-regulated upon 
mating, and where the change was reduced by 
mifepristone/RU486. Several candidate positive 
regulators of life span were identified that are 
conserved in humans, including dosage compensation 
regulator Unr and the Dopamine 2-like receptor.  
Candidate negative regulators included neuropeptide 
CNMamide and several involved in protein 
mobilization and immune response, including the 
AMP gene Drosocin.  Analysis of Drosocin-GFP 
reporters in live flies recapitulated the aging-
associated inflammation, including the effects of mating 
and mifepristone/RU486.The results implicate steroid 
hormone signaling in regulating sex-specific trade-offs 
between reproduction versus immune function and 
longevity. 
 
Vadim Fraifeld (Ben-Gurion University of the Negev) 
“Mitochondria: a bottleneck of aging and longevity?” 
Nuclear-mitochondrial relationships could be 
characterized as “enslaving” rather than symbiosis. 
Indeed, mitochondria are the most “hard-working” 
organelles in the animal cell, which have delegated the 
vast majority of the genes to the nuclear genome. This 
situation inevitably brings about to a “conflict of 
interests”, with far-reaching consequences. Unsurprising-
ly, mitochondria-associated variables (mtDNA GC 
content, metabolic rate, metabolic score, body 
temperature) are powerful predictors of mammalian 
longevity, and thus could be considered the main targets 
for longevity-promoting interventions.  
Vera Gorbunova (University of Rochester) “The 
mechanisms of more efficient DNA repair in long-lived 
mammals: the role of SIRT6”. 
  
Blanka Rogina (University of Connecticut Health) 
“Indy reduction maintains fly health and homeostasis”. 
Indy (I’m not dead yet) encodes the fly homologue of a 
mammalian transporter of the Krebs cycle 
intermediates. Reduced Indy gene activity has beneficial 
effects on energy balance in mice, worms and flies, and 
worm and fly longevity. In flies, longevity extension is 
not associated with negative effects on fertility, mobility 
or metabolic rate. Others and we show that Indy 
reduction extends longevity by mechanism similar to 
calorie restriction (CR). Some of the hallmarks of these 
changes are altered intermediate nutrient metabolism, 
increased spontaneous physical activity and increased 
mitochondrial biogenesis. These changes have been 
found in fly heads, thoraces and the midguts. The 
observed changes in midgut energy metabolism, 
specifically decreased production of free radicals, 
results in preservation of intestinal stem cell (ISC) 
homeostasis and midgut integrity. Our studies show a 
direct link between changes in energy metabolism, 
caused by the Indy reduction and preservation of ISC 
homeostasis. The data suggest that Indy reduction 
preserves homeostasis in tissues that contribute to 
extended health and longevity. 
 
Elena Pasyukova (Institute of Molecular Genetics of 
Russian Academy of Sciences, Russia) “Neuronal 
transcriptional regulators of lifespan in Drosophila 
melanogaster”. 
  
Irina Irincheeva (Nestlé Institute of Health Sciences) 
presented “Why don't we all lose weight equally on 
Caloric Restriction?" Proteomics explanation to weight 
loss variability on a low-calorie diet in overweight and 
obese subjects” Obesity is characterized by a state of 
metabolic inflexibility and chronic inflammation 
leading to the development of comorbidities like type 2 
diabetes, dyslipidemia or certain cancers and generally 
to a decreased life expectancy in obese individuals. Low 
calorie diets (LCD) (<1000 kcal per day) have been 
shown to be very effective in improving many of the 
metabolic dysfunctions. However, the capacity to lose 
weight and the associated metabolic improvements 
show significant variability in humans, even under the 
same controlled dietary regimes. To understand the 
molecular basis for these differences we screened the 
plasma expressions of over twelve hundred proteins in 
500 overweight and obese subjects to determine 
whether we could predict at baseline the weight loss 
outcome of 8 weeks LCD diet (800 kcal per day). As 
discovery data to construct a weight loss predictive 
model we used the Pan-European cohort DiOGenes 
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(Diet, Obesity and Genes, Larsen et al., 2010). To select 
weight loss predictive proteins we deployed elastic net 
bootstrap estimation of high-dimensional regression 
(Chatterjee and Lahiri, 2011) adjusting for gender, age 
and BMI at baseline. We evaluated the accuracy of our 
predictive model on the data set of 500 independent 
subjects from Ottawa Hospital Weight Management 
Clinic using LCD for weight loss. The accuracy of the 
predictive model was significantly higher than random 
in the independent data set. 
  
To identify functional relationships and biochemical 
pathways shared between the predictive proteins we 
performed network analyses. The results allow us to 
formulate a first hypothesis on biological processes 
leading to successful weight loss for overweight and 
obese subjects on a low-calorie diet.  
  
Alexander Kulminski (Duke University) presented 
“Uncoupling associations of risk alleles with 
endophenotypes and phenotypes: Insights from the 
Apolipoprotein B locus, lipids, myocardial infarction, 
and survival”. Traditionally, genome-wide association 
studies (GWAS) have emphasized the benefits of large 
samples in the analyses of age-related traits rather than 
their specific properties. We adopted a realistic concept 
of genetic susceptibility to inherently heterogeneous, 
age-related traits driven by the elusive role of evolution 
in their properties. We analyzed in detail the 
associations of rs693 and rs562338 polymorphisms 
representing the Apolipoprotein B locus with 
endophenotypes (total cholesterol [TC] and high-
density lipoprotein cholesterol) and phenotypes 
(myocardial infarction [MI] and survival) in four large-
scale studies. We showed that a strong, robust 
predisposition of rs693 and rs562338 to TC (beta=0.72, 
p=7.7×10-30 for rs693 and beta=-1.08, p=9.8×10-42 for 
rs562338) is not translated into a predisposition to MI 
and survival. The rs693_A allele influences risks of MI 
and mortality for MI patients additively with lipids. 
This allele shows antagonistic effects -- protecting 
against MI risks (beta=-0.18, p=1.1×10-5) or increasing 
MI risks (beta=0.15, p=2.8×10-3) and mortality for MI 
patients, in different populations. Paradoxically, 
increased TC concentrations can be protective against 
MI for the rs693_A allele carriers. Our results uncouple 
the influences of the same alleles on endophenotypes 
and phenotypes despite potential causal relationships 
among the latter. Our strategy reveals an overall highly 
significant association of rs693 with MI (p=5.5×10-8) 
that is contrasted with a weak estimate following the 
traditional, sample-size-centered GWAS strategy 
(p=0.16) in the same sample. These results caution 
against the use of the traditional GWAS strategy for 
gaining profound insights into genetic predisposition to 
healthspan and lifespan. 
Vladimir Skulachev (Moscow State University) in his 
lecture “Naked Mole Rats and Humans: Highly Social 
Creatures Prolonging Youth by Delay of Ontogenesis 
(Neoteny)” considered some physiological mechanisms 
responsible for longevity of eusocial mammals, i.e. a 
rodent (naked mole rat) and a primate (human). It is 
concluded that both naked mole rat and human are no 
more affected by dynamic natural selection due to 
specific organization of the socium (naked mole rat) and 
substitution of fast technical progress for slow 
biological evolution (human). Since aging is supposed 
to be a program stimulating evaluability by increasing 
pressure of natural selection upon an individual, such a 
program became a harmful atavism for naked mole rat 
and human. This is apparently why aging as a reason for 
death is very rare in naked mole rats younger than 30 
years and humans younger than 55 years. Such an effect 
is achieved, at least partially, by prolongation of youth 
(neoteny). The numerous facts are described indicating 
that The Master Biological Clock responsible for timing 
of ontogenesis is retarded both in naked mole rat and in 
human. In these species, numerous traits of youth do not 
disappear (or disappear enormously slowly) with age.  
For a long time, in naked mole rat, this point of view 
was supported mainly by morphological observations, 
such as absence of hair, auricles and scrotum, 
underdevelopment of lungs, etc. Recently, numerous 
physiological features of neoteny in naked mole rat 
were described.  Among them are (i) long gestation, (ii) 
long maturity time, (iii) strong delay in brain 
development, (iv) regeneration and elongation of 
neurons during entire life span, (v) extremely high 
resistance of adult mole rat neurons to 
anoxia/reoxigenation, a property inherent in newborn 
and young, but not adult mammals, (vi) resistance to 
H2O2 - induced apoptosis of cell culture, (vii) absence 
of age-linked decay in levels of antioxidants (in 
particular, due to very high concentration of 
extracellular antioxidant hyaluronan), (viii) absence of 
any increase in peroxidation index of lipids with age, 
(ix) no age-linked increase in ROS production, (x) 
retarded postnatal development of mitochondrial 
reticulum in skeletal muscles, (xi) absence of decay in 
the amount of mitochondria with age, (xii) no age-
induced decay in proteasome level, (xiii) no indications 
of aging of immune system, (xiv) low transcription of 
genes and activity of insulin and IGF1 and high 
transcription and activity of IGF2, etc. These and other 
specific features of the naked mole rats explain their 
resistance to cancer, infections, cardiovascular and brain 
diseases, diabetes, and, as a result, their long maximal 
lifespan, which is more than 30 years vs. 3.5 years for 
mice (a rodent of the similar size). 
 
For humans, it is generally accepted that embryo, 
neonatanal and young organisms have features similar 
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to other primates, thereby the listed morphs resemble 
very much human, not ape. As to the ape-specific traits 
(a lot of hair on the body, construction of the skull, 
large superciliary arches, etc.), they appear in adulthood 
of animals and do not appear in humans. Recently, 
studies of brain transcriptomes of humans, chimpanzees 
and rhesus macaques revealed that in humans, just like 
naked mole rats, transcription of large group of genes is 
strongly retarded compared to the great apes. 
Comparison of pairs of highly and lowly social 
mammals (naked mole rat vs. mouse and human vs. 
chimpanzee) is very interesting. In both pairs, highly 
social representative (i) is long-lived, (ii) its age-
dependent mortality during first 30-55 years is so low 
that its contribution to the total mortality is negligible, 
(iii) gestation and maturation times are longer, (iv) brain 
development is strongly retarded but without negative 
effect on the final mass of the organ, (v) skeletal muscle 
development is also retarded resulting in lowering in the 
final mass. 
 
Demonstration of neoteny in humans at physiological 
and genetic levels is very important for understanding 
of physiological, pathological and therapeutic aspects of 
aging. In particular, prolongation of youth by delay of 
aging is impossible to imagine within the framework of 
the concept of stochastic (non-programmed) aging but 
can easily be explained if aging is programed and 
controlled by The Master Biological Clock, like other 
main steps of ontogenesis. Arrest of operation of aging 
program in humans by an antiaging medicine seems to 
be a promising approach to prolong our healthspan. 
  
David Gems (University College London) spoke on 
"The origins of senescent pathology in C. elegans". The 
biological mechanisms at the heart of the aging process 
are a long-standing mystery. An influential theory has it 
that aging is the result of an accumulation of molecular 
damage, caused in particular by reactive oxygen species 
(ROS) produced by mitochondria. This theory also 
predicts that processes that protect against oxidative 
damage (involving detoxification, repair and turnover) 
protect against aging and increase lifespan. However, 
recent tests of the oxidative damage theory, some using 
the short-lived nematode worm C. elegans, have often 
failed to support the theory. This motivates 
consideration of alternative models. One new theory, 
conceived by M.V. Blagosklonny and based on the 
antagonistic pleiotropy theory of G.C. Williams, 
proposes that aging is caused by the non-adaptive 
running on in later life of developmental and 
reproductive programmes. Such quasi-programmes (i.e. 
that are genetically programmed but non-adaptive) give 
rise to hyperfunction, i.e. functional excess due to late-
life gene action, leading via dysplasia (including 
hypertrophy and hyperplasia, and atrophy) to the age-
related pathologies that cause the late-life increase in 
mortality. Here we assess whether the hyperfunction 
theory is at all consistent with what is known about C. 
elegans aging, and conclude that it is. In particular, 
during aging C. elegans show a number of changes that 
may reflect pathology and/or hyperfunction, including 
oocyte hypertrophy to form tumor-like masses, 
proximal gonad atrophy and disintegration, massive 
yolk accumulation, cuticular hypertrophy and neurite 
outgrowth. Such changes are retarded in long-lived 
mutants, and can contribute to mortality. We 
demonstrate how futile run-on of yolk synthesis, 
conversion of intestinal biomass into yolk, and germline 
apoptosis generate late-life pathology. Our assessment 
implies that the hyperfunction theory is sufficient to 
explain the origins of major senescent pathologies in C. 
elegans, i.e. is a major cause of aging in this organism. 
The relative importance of hyperfunction and molecular 
damage as causes of different senescent pathologies in 
different organisms, and the interactions between these 
two major senescent etiologies are important topics for 
future investigation. 
  
Vadim Gladyshev (Harvard Medical School) “The 
rising deleteriome”. Understanding the nature of aging 
is an important step in developing approaches to 
manipulate it. Various theories posit that aging may be 
caused by molecular damage, genetic programs, 
continued development, hyperfunction, antagonistic 
pleiotropy alleles, mutations, trade-offs, incomplete 
repair, etc. I will discuss that these ideas can be 
conceptually unified as they capture particular facets of 
aging. Living is associated with a myriad of deleterious 
processes, both random and deterministic, which exhibit 
cumulative properties, and represent the indirect effects 
of biological functions at all levels, from simple 
molecules to systems. From this, I derive the 
deleteriome, which encompasses cumulative deleterious 
age-related changes and represents the biological age. 
The organismal deleteriome consists of the deleteriomes 
of cells, organs, and systems, which change along 
roughly synchronized trajectories and may be assessed 
through biomarkers of aging. Aging is then a 
progressive decline in fitness due to the increasing 
deleteriome, adjusted by genetic, environmental, and 
stochastic processes. I will discuss how the deleteriome 
can be analyzed by following increased molecular 
damage in the form of low molecular weight species, 
somatic mutations derived from the analysis of cancer 
genomes, and dietary approaches.   
  
Arnold Mitnitski (Dalhousie University) reported “A 
dynamical network model for age-related accumulation 
of health deficits and mortality”. How long people live 
depends on their health, and how it changes with age. 
Individual health can be tracked by the accumulation of 
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age-related health deficits. The fraction of age-related 
deficits is a simple quantitative measure of human 
aging. This quantitative frailty index is as good as 
chronological age in predicting mortality. It has been 
shown that the accumulation of deficits is related to age 
associated imbalance between damage and repair 
processes, at the different levels of the organism. What 
causes such an imbalance was not clear. In order to 
answer this question, we developed a dynamical 
network model of aging.  An individual was represented 
by a network of connected deficit nodes (n=800), each 
of which has two stable states corresponding to health 
and damaged. In our model, damage and repair rates 
have no explicit time-dependence, but do depend on the 
state of connected nodes. Transitions between the states 
were governed by: (i) interactions between the nodes, 
i.e. network connectivity, and; (ii) the environment, 
with a general stochastic mechanism (white noise) 
representing the environment.  With this model, we 
observed upward curvature of the frailty index and 
broadening the distribution of the frailty index with age. 
We use a simple mortality criterion, where mortality 
occurs when the most connected node is damaged. In 
this way, we qualitatively reproduce Gompertz's law of 
exponential increasing human mortality with age. No 
explicit time-dependence in damage or repair rates was 
needed in our model. Instead, implicit time-dependence 
arose through deficit interactions - so that the average 
deficit damage rates increased, and deficit repair rates 
decreased, with age. We discuss the implication of our 
computational model that will allow us to start with 
high-quality model data, before we test our insights 
against current and emerging clinical data. 
  
S. Michal Jazwinski (Tulane University Health 
Sciences Center) presented “Metabolic and Genetic 
Markers of Biological Age”. Biological and 
chronological age are not the same, as individuals 
depart in health from the average.  Taking a systems 
approach, we developed an objective measure of 
healthy aging, a frailty index (FI34) composed of 34 
health and function variables.  FI34 is a much better 
predictor of mortality than is chronological age; 
therefore, it directly reflects biological age.  It increases 
exponentially with chronological age, but it does so 
more slowly for offspring of long-lived parents.  FI34 is 
also heritable (h2=0.39).  Thus, it can be used in genetic 
analyses.  The patterns of aging described by the 
variables in FI34 are very different for offspring of 
long-lived and short-lived parents.  We have examined 
the association of the components of energy metabolism 
with FI34 in the oldest-old.  Surprisingly, there is a 
positive association of FI34 with resting metabolic rate 
(RMR).  This points to the rising cost of maintenance of 
integrated body function with declining health during 
aging.  There are differences between males and 
females, however.  In males, circulating creatine kinase 
(CK) increases with FI34.  A decline in fat-free mass 
(FFM) is found instead in females.  The CK increase in 
males is associated with variation in the genes XRCC6 
and LASS1.  These genes have in common a role in cell 
death, suggesting tissue damage as a source of increased 
energy costs of maintenance with declining health in 
males.  In females, there is an association of variants of 
UCP2 and UCP3 with FI34, which is not found in 
males.  These genes encode mitochondrial membrane 
transporters that impact cell metabolism.  An interaction 
of a functional variant of UCP3 with RMR explains the 
association with FI34.  We have used FI34 in an 
unbiased screen for genomic variation associated with 
healthy aging.  This uncovered a region on chromosome 
12 associated with this phenotype.  Fine-mapping 
dissects this into three sites, which bear marks of 
regulatory function and association with longevity.  
Supported in part by grants from the National Institutes 
of Health (NIH). 
 
Aubrey de Grey (SENS Research Foundation) spoke 
on "Longevity escape velocity: incorporating 
technological progress into extrapolation". Predictions 
of future longevity have historically failed, by and large, 
to prove accurate. I will argue that this is because they 
are in one or another way based on pure extrapolation of 
past trends, a method that incorporates the implicit 
assumption that it does not matter *how* we contrived 
to achieve longevity improvements. I will explain how a 
careful examination of the medical and other advances 
that led to increased longevity could have resulted in 
much better predictions of their impact. I will then focus 
on the future, and especially on the initially 
counterintuitive but ultimately inescapable conclusion 
that regenerative medicine applied to the health 
problems of old age will at some point, probably within 
the next few decades, create a sharp discontinuity - 
which others have termed the “Methuselarity” - in the 
longevity of successive cohorts. This discontinuity will 
be so dramatic that period life expectancy will literally 
cease to be calculable, because mortality rates for all 
ages so far attained will become so low that survival 
probabilities will multiply to more than 50%. 
  
Daniel Belsky (Duke University) presented 
“Quantification of biological aging in young adults”. 
Population aging threatens to bring a tidal wave of 
disease and disability (1). Strategies to prevent or treat 
individual diseases will be inadequate to contain costs 
and preserve economic productivity; interventions that 
address the root cause of multiple diseases 
simultaneously are needed. Such “geroprotective” 
interventions are emerging from model organism 
studies. Translation of these interventions to humans is 
slowed by the need for lengthy follow-up to evaluate 
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effectiveness. This is especially true in the case of 
interventions that will need to be applied to young 
humans free of age-related disease, for whom 
prevention is still possible. Thus, surrogate endpoints 
for trials of geroprotective interventions are needed. 
Because most human aging research examines older 
adults, many with chronic disease, little is known about 
aging in young humans. We studied aging in 954 young 
humans, the Dunedin Study birth cohort. To quantify 
biological aging in these individuals, we tracked 
multiple biomarkers across three time points spanning 
their 20s and 30s. We devised a longitudinal measure 
that quantifies the pace of coordinated physiological 
deterioration across multiple organ systems (e.g., 
pulmonary, periodontal, cardiovascular, renal, hepatic, 
and immune function). This measure, the “Pace of 
Aging,” showed substantial variation in young, healthy 
adults who had not yet developed age-related disease. 
Young adults with faster Pace of Aging were, by 
midlife, less physically able, showed cognitive decline 
and brain aging, self- reported worse health, and looked 
older. The number of assays and repeated measurements 
required to assess Pace of Aging make it impractical for 
large-scale geroprotector trials. Biological aging 
measures that can be implemented in a single cross-
section of data at baseline and follow-up are needed. 
We examined Pace of Aging alongside several, more 
scalable cross-sectional measures of biological aging. 
These measures were based on clinical biomarker and 
genomic data, including two recently published clinical-
biomarker algorithms, telomere length, and epigenetic 
clocks. We asked two questions: (1) Do different 
measures of biological aging measure the same thing? 
and (2) Do different measures of biological aging 
capture different information about healthspan? 
Findings suggest promise and challenges in research to 
develop surrogate endpoints for trials of geroprotective 
interventions. 
  
Andreas Simm (Martin Luther University Halle-
Wittenberg) presented “Biomarkers of Ageing: the 
what-where from-when questions”. 
  
Tamas Fülöp (University of Sherbrooke) presented 
“Are there any reliable biomarkers for immuno-
senescence?”. Aging is accompanied by many 
physiological changes including those related to the 
changes in the immune system. These changes are 
called Immunosenescence which is accompanied by the 
Inflamm-aging phenomenon. Many biomarkers have 
been proposed to describe these age-associated changes 
in the immune system. One of the most consistent is the 
chronic Cytomegalovirus infection. Most of the elderly 
are affected in developed countries which about 70% 
and in developing countries about 100% at the age of 
80. Despite the numerous studies there is no consensus 
which role the recurrent CMV infections play in the 
alterations of the immune system namely in the 
Inflamm-aging process and in the more consistent 
phenotypic alterations of T cells. Many experimental 
evidence supports that changes observed with aging 
(increase of memory CD8+ T cells, increase in pro-
inflammatory cytokine mediators) may be related to 
chronic CMV infections. However, this infection was 
also showed to be a promoter of a better immune 
response in some cases e.g. vaccination.  There is still 
debate whether CMV infection causes the immuno-
senescence which in this case would suggest that aging 
of the immune system is nothing else, but just a viral 
infection. In contrast, if this is just a concomitant 
phenomenon thus in this case we should target other 
biomarkers which would represent the immuno-
senescence. There is much confusion between diseases 
and biological aging, thus one of the main tasks is to 
define biological aging. Longitudinal studies combined 
with healthy very old elderly persons studies may give 
some clue to this and may help to find earlier 
biomarkers to reflect biological aging changes and 
eventually modify them.    
  
Joao Pedro de Magalhaes (University of Liverpool) 
presented on “Gene expression profiling for the 
discovery of biomarkers of ageing”. There is 
widespread interest in identifying biomarkers of ageing 
in order to accelerate basic and translational research. 
Our lab has employed various gene expression profiling 
approaches to identify molecular signatures that can be 
used as biomarkers as well provide functional insights 
on ageing and its manipulation. We performed a meta-
analysis of ageing gene expression profiles using 
microarray datasets from multiple mammalian tissues, 
which revealed several conserved molecular signatures 
of ageing. We also applied our network and meta-
analysis methods to dietary manipulations of ageing, in 
particular caloric restriction (CR), and identified 
candidate genes and processes strongly associated with 
CR in mammals. Moreover, we have been employing 
whole transcriptome profiling (RNA-seq) to study 
ageing and its manipulation by diet, which has 
significant advantages when compared to microarrays. 
Lastly, to catalogue and help understand ageing 
changes, we developed the Digital Ageing Atlas 
(http://ageing-map.org/), a one-stop collection of human 
age-related data covering different biological levels 
(molecular, cellular, physiological, psychological and 
pathological). 
  
Arnold Mitnitski (Dalhousie University) reported 
“Indices of biological aging as indicators of 
heterogeneity of people’s health”. There is an increasing 
interest to assessing biological aging - the aging rates 
are different in individuals of the same chronological 
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age.  Some found attractive an idea that these 
differences reflect differences in “biological age”.  How 
to estimate biological age is a matter of ongoing 
debates. The techniques differ also depending on which 
biomarkers are used to calculate of biological age. We 
discuss the different approaches to estimation of 
biological age based on biomarkers of aging of different 
nature: from the sub-cellular level to the level to the 
whole organism.  We consider this issue from the 
heterogeneity of people at the same chronological age 
perspective, from which the index of biological age is 
only one of possible measures of such heterogeneity.  
We illustrate some challenges in assessing biological 
age, by comparing a few measures of heterogeneity: the 
indices of biological age, defined with and without 
chronological age, and the frailty indices. By providing 
head-to-head comparison of these measures we 
demonstrated that inclusion of chronological age in the 
measure of biological age is unnecessary, and also (at 
least in the data sample we present) inferior to the 
frailty indices.  The latter are based on the higher 
number of biological and clinical data therefore more 
likely capture the essential characteristics of health and 
its changes during aging, than a rather restricted set of 
biomarkers used to calculate biological age score.  Also, 
the items used to calculate the frailty indices are readily 
available (either from the routine blood tests or/and 
from clinical assessments), the algorithm of its 
assessment is simple, in contrast to the obscured 
statistical techniques of calculating the biological age 
scores from a relatively restricted number of continuous 
biomarkers. Extensive comparisons across different 
databases are required.  We discuss the problem of 
integration of various biological/clinical in a unified 
index of biological age. 
  
Alexander Kulminski (Duke University) reported 
“Can age-specific genetic effects be relevant to 
biological age?”. Living organisms are getting older and 
eventually die at a certain age. The actual time an 
organism has been alive refers to chronological age 
(CA). However, not all organisms die at the same 
chronological age even if they are of the same species. 
The idea of biological age (BA) is that the differences in 
lifespan of these organisms can be due to an internal 
clock. For humans, BA refers to how old that human 
seems. A problem, however, is how to quantify BA. A 
promising approach could be to express BA in terms of 
measurable phenotypes such as biomarkers. As 
phenotypes, biomarkers represent endpoints of a 
cooperative work of genes in an organism. Accordingly, 
BA could readily have a genetic origin. Does it 
necessarily imply that there should be specific genes 
regulating BA? The answer is not straightforward. 
Associations of BA with telomere length seems to 
support existence of BA-specific genes. However, 
studies of laboratory animals show that even genetically 
the same organisms can have dramatically different 
lifespan even if they are in the same, perfectly 
controlled environment. These and other findings 
suggest that BA can be modulated not only by the BA-
specific genes but also by changes in the effects of other 
genes over CA. Studies show that epigenetic 
modifications can modulate the effects of genes over 
CA. What about genes themselves, do they influence 
the same phenotypes differently at different ages? It is 
often assumed that genes have age-independent effects 
on phenotypes. In this presentation, we will discuss 
evidence of the changing role of genes in human 
phenotypes with age. 
  
Alex Zhavoronkov, Evgeny Putin, Alex Aliper, 
Mikhail Korzinkin (Pharmaceutical Artificial 
Intelligence Department, Insilico Medicine, Inc.) 
presented a talk on “Gamification of data collection for 
deep learning and biomarker development”. Since the 
publication of Horvath’s epigenetic aging clock in 2013, 
the field of aging biomarkers is rapidly evolving with 
epigenetic and transcriptomic markers developed to 
accurately predict chronological age of the patient. 
However, since these tests are reasonably new and 
expensive, the number of samples with clinical 
outcomes is still low making it difficult to assess the 
biological relevance and facilitate for rapid clinical 
propagation. 
 
One data type, medical professionals have a lot of 
experience with, which is abundant, cost-effective and 
actionable is clinical blood and urine tests commonly 
including basic blood biochemistry and cell counts. 
Millions of clinical profiles with blood biochemistry 
data are available worldwide providing sufficient 
number of samples to train deep neural networks.   
 
We obtained a large data set of standard blood tests with 
41 parameters linked to age and sex of the patients from 
Invitro Laboratories, one of the largest providers of 
laboratory services in Eastern Europe. The data set 
contained over 60,000 samples coming from routine 
checkups and excluded sources of patients with diseases 
like hospitals and medical institutions. We trained 21 
single class deep neural networks ensembled using a 
stacking model to predict the patients’ chronological 
age with 83.5% epsilon-accuracy r of 0.91 with R(2) of 
0.82 and mean absolute error (MAE) of 5.55 years.  
 
Following on the footsteps of Microsoft’s 
http://www.how-old.net, we built a website 
http://www.aging.ai inviting people from all over the 
world to submit their test results in order to guess their 
age. From January 15 to March 31st over 1,500 people 
participated in the study. In addition to blood tests we 
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asked to provide height, weight and smoking status, the 
new parameters that are being evaluated for the future 
studies. We plan to expand Aging.AI system to work 
with urine, transcriptomic and imaging data and 
welcome collaborations in building comprehensive and 
actionable biomarkers of aging.  
 
Ivan V. Ozerov (Senolytics Department, Insilico 
Medicine, Inc.) presented “iPANDA identifies the 
pathway signature in senescent cells: a step forward to 
development of novel senolytic drugs”. Cellular 
senescence combined with an inability of immune 
system to effectively eliminate senescent cells leads to 
persistent accumulation of senescent cells in an aging 
organism. On the other hand, senescent cells represent a 
constant danger to the cell population as far as they 
partly lose their functions and induce malfunctioning of 
surrounding cells. As senescent cells accumulate in 
even greater numbers over the years, the whole tissues 
gradually loose their specific properties. Such process 
results in developing of aging phenotype and 
encourages the risk of malignant transformation in the 
affected cells. Hence therapies aimed to selectively 
eliminate senescent cells have a potential to slow down 
age-related changes in tissues and body in whole as well 
as to reduce the risks of cancer generation. Recently 
three low-molecular compounds which demonstrate an 
ability to selectively eliminate senescent cells in various 
tissues were proposed. This novel class of prospective 
drugs is referred to as senolytics. 
 
In this study, we apply our recently-developed approach 
to large-scale transcriptomic data analysis in silico 
Pathway Activation Network Decomposition Analysis 
(iPANDA) to identify pathway signatures of senescent 
cells in various tissues and pathway signatures of 
known senolytic drugs. iPANDA algorithm is 
specifically designed to obtain robust results when 
analyzing transcriptomic data from multiple sources. 
Thus, we were able to extract the common tissue-
independent features of senescent cells including 
downregulated anti-apoptosis signalling networks as 
well as several tissue-specific features of cellular 
senescence. In order to find novel compounds with 
senolytic properties we utilized this information for 
obtaining a list of prospective protein targets. A list of 
about 100 low-molecular senolytic candidates was 
derived partly from the pharmacophore-based scanning 
of proposed protein targets and partly from a list of 
known drugs which selectively affect the identified 
pathways involved in cellular senescence. At present 
moment, the validation process of these compounds in 
cell culture experiments is on the way. 
 
Ksenia Lezhnina and colleagues (Insilico Medicine, 
Inc.) presented “Signaling pathways signature of 
sarcopenia identified by iPANDA algorithm.” 
Sarcopenia is a losing muscle mass and function with 
aging. Decreased strength and power of muscle function 
may contribute to higher risks of accidents among older 
people and affects quality of life. Until recently 
sarcopenia was not even considered as a pathological 
condition and as a consequence clinical definition and 
diagnostic criteria is poorly developed. Mechanism 
underlying sarcopenia is extensively investigated but 
still not fully understood. In order to study this we 
compare transcriptomic profiles of muscle tissues from 
young and old people, both women and men. We 
assume that aging process starts from the fourth decade 
of life. We apply a new algorithm in silico Pathway 
Activation Network Decomposition Analysis 
(iPANDA) to transcriptomic data to find signaling 
pathway signatures of aging in muscle tissues. Common 
pathway signatures can be considered as a target for 
development of new approaches for sarcopenia 
treatment. 
 
Artem Artemov and colleagues (Insilico Medicine, 
Inc.) presented "In silico screen for drugs increasing 
cancer immunotherapy success rates". Cancer 
immunotherapy has been shown to be extremely 
efficient. Unlike traditional targeted therapy, it can lead 
to a complete remission rather than a few months 
increase in lifespan. Unfortunately, it is beneficial for 
only a small subset of patients. In this work, we 
performed in silico screening of compounds which can 
be administered in combination with anti-PD1 
immunotherapy to increase immunotherapy success 
rate. We collected publicly available transcriptome data 
for tumours responding and not responding to 
immunotherapy. Next, we applied iPANDA, Insilico 
medicine pathway analysis algorithm, and deep-learning 
based approach to identify a transcriptomic signature 
predicting the success of immunotherapy in a particular 
tumour. Finally, we analyzed drug-induced 
transcriptome effects to screen for the drugs which 
could robustly drive transcriptomes of tumour cells 
from non-responsive state to the state responsive to 
immunotherapy. Among the top-scoring drugs we found 
known compounds used in combination with cancer 
immunotherapy. Interestingly, we also found a 
compound which was a close chemical analog to a 
compound used in cancer immunotherapy, but hadn't 
itself been studied for this indication. This approach, 
after preclinical and clinical validation, may lead to 
improved cancer care and dramatic lifespan increase of 
cancer patients. 
 
Polina Mamoshina and colleagues (Insilico Medicine, 
Inc.) presented "In silico modeling of human skin 
permeability of compounds with possible geroprotective 
activity" Despite the fact that many chemicals 
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demonstrate potential skin rejuvenating activity, skin 
aging is still an incurable process. The major problem is 
that most of the anti-aging compounds have low skin 
penetration level and so bioavailability. Dermal 
absorption rate could be estimated by in vitro and in 
silico approaches. We utilized a set of Machine 
Learning techniques to predict skin permeability 
coefficient (Kp) of compounds with skin geroprotective 
activity. K-nearest neighbors algorithm showed the best 
performance with r=0,94, R2=0,86, MAE=0,29. This 
new approach may lead to a development of new 
effective remedies that could slow down or even reverse 
skin aging.   
 
Jane Schastnaya (Insilico Medicine, Inc.) presented 
“iPANDA for biomarker identification in aging-
associated hair loss”. In silico Pathway Activation 
Network Decomposition Analysis (iPANDA) is a novel 
biomathematical method, which has a potential to be a 
universal tool for pathway activation analysis in the 
treatment of anti-aging diseases and for the 
identification of actionable targets for therapy. It can be 
used for the analysis of any physiological, stress, 
malignancy and other perturbed conditions at the 
molecular level. We showed the results of a qualitative 
analysis of signaling pathway activation state in 
androgenetic alopecia. Some of these signaling 
pathways may serve as targets for the treatment of hair 
growth disorders. For example, recent findings 
demonstrated that inhibition of JAK-STAT signaling 
pathway can promote hair growth. Further progress in 
research will lead to the increasing insight into 
pathways involved in pathological hair cycling. 
  
Alexander Fedintsev and Alexey Moskalev (Moscow 
Institute of Physics and Technology) presented 
“Markers of cardiovascular health for human 
chronological and biological age estimation”. The aging 
process is unavoidably associated with a decline in 
functional physical capacity. A lot of anti-aging 
interventions are known but they were tested only on 
model organisms so it is very important to develop 
simple, cheap and accurate method of biological age 
estimation which can be used to control anti-aging 
therapy efficacy. To develop such a method, we 
performed analysis using machine learning approach to 
reveal parameters which are mostly associated with 
chronological age and selected four of them. These four 
predictors which showed highest importance are: 
complex intima media thickness, arterial stenosis, 
augmentation index, and pulse wave velocity. The 
combined index composed of these four parameters 
explained up to 61% of variance in age, more than other 
biomarkers of age like telomere length or glycans. We 
also measured median absolute error which was 5.12 
years for women and 5.46 years for men. These four 
parameters reflect aging of cardiovascular system. 
Cardiovascular diseases are the major cause of age-
related mortality so we assume that our method is good 
estimation not only of chronological but also of 
biological age. In addition, this method uses medical 
equipment which is widely represented in modern 
clinics. 
  
Peter Fedichev (Gero, Inc.) in his report “Target and 
biomarker identification platform to design new drugs 
against aging and age-related diseases” studied 
fundamental aspects of aging to develop a mathematical 
model of gene regulatory network. We show that aging 
manifests itself as an inherent instability of gene 
network leading to exponential accumulation of 
regulatory errors with age. To validate our approach, we 
studied age-dependent omic data such as 
transcriptomes, metabolomes etc. of different model 
organisms and humans. He builds a computational 
platform based on our model to identify the targets and 
biomarkers of aging to design new drugs against aging 
and age-related diseases.  As biomarkers of aging we 
choose the rate of aging and the biological age since 
they completely determine the state of the organism. 
Since rate of aging rapidly changes in response to an 
external stress, this kind of biomarker can be useful as a 
tool for quantitative efficacy assessment of drugs, their 
combinations, dose optimization, chronic toxicity 
estimate, personalized therapies selection, clinical 
endpoints achievement (within clinical research), and 
death risk assessments. According to the model were 
proposed a method for targets identification for further 
interventions against aging and age-related diseases. 
  
Anatoliy Yashin (Duke University) reported “Lack of 
Replication in GWAS of Complex Traits: Insights for 
Efficient Analyses of Human Aging and Longevity”. 
The genome-wide association studies (GWAS) 
performed during the last decade detected a large 
number of SNP loci that influence variability of human 
aging, health, and longevity related traits. While many 
of these findings were confirmed in analyses of 
independent populations many other identified 
associations remain non-replicated. The persistent non-
replication of the research results indicates a problem 
that needs immediate attention. The purpose of this 
paper is to investigate the possible contribution of 
population genetic structure to this problem. We 
reviewed the results of recent GWAS of longevity 
related traits and investigated forces and mechanisms 
that form genetic structures of human populations. We 
found that these structures may differ in populations 
used in genetic association studies. We investigated the 
role of linkage disequilibrium (LD) between functional 
SNPs on estimates of the effects of these SNPs on 
mortality risks.  We found that the estimates of genetic 
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associations of minor allele in the first locus with 
lifespan as well as age trajectories of mortality rates for 
carriers and non-carriers of this allele are strongly 
modulated by the levels of LD between the two loci. 
Depending on the LD levels between these SNPs the 
same genetic variant may have positive, negative, or no 
association with longevity related trait. The estimated 
associations may also change with increasing age from 
positive to negative and vice versa. The results of these 
analyses indicate that the difference in LD between the 
two functional SNP loci in the two study populations 
may contribute to the lack of replication of the results of 
genetic association studies of human longevity related 
traits.  These results also show that studying LD 
patterns around functional SNPs, as well as effects of 
haplotypes on longevity related traits may contribute to 
better understanding the genetic nature of these traits. 
  
Alexander Maslov (Albert Einstein College of 
Medicine) presented “Quantitative assessment of 
genome integrity by high-throughput sequencing: 
application for aging research”. Aging is a complex trait 
governed by both genetic and environmental factors. 
While environmental exposure promotes genome 
instability, a major driver of the aging process, 
genetically determined mechanisms of genome 
maintenance act in the opposite direction and promote 
longevity. The idea that environmental hazards promote 
aging is not novel. Twin studies have demonstrated that 
environmental factors play an important role in the 
development of degenerative diseases associated with 
aging and that the relative contribution of non-genetic 
factors increases in advanced ages. However, until 
recently these studies had a mostly descriptive 
character; now since the advent of new technologies in 
genetic research, predominantly next-generation 
sequencing, we are capable of taking this a step further 
and directly assess genome integrity in primary cells or 
tissues of any species. 
  
Matt Kaeberlein (University of Washington) presented 
“Effects of transient mid-life rapamycin treatment on 
lifespan and healthspan”. The FDA approved drug 
rapamycin increases lifespan and improves measures of 
healthspan in rodents [1]. Nevertheless, important 
questions exist regarding the translational potential of 
rapamycin and other mTOR inhibitors for human aging, 
and the optimal dose, duration, and mechanisms of 
action remain to be determined [2]. Here I will report on 
studies examining the effects of short-term treatment 
with rapamycin in middle-aged mice and dogs.  We find 
that transient treatment with rapamycin is sufficient to 
increase life expectancy by more than 50% and improve 
measures of healthspan in middle-aged mice. This 
transient treatment is also associated with a remodelling 
of the gut microbiome, including dramatically increased 
prevalence of segmented filamentous bacteria in the 
small intestine, along with a dramatic shift in the cancer 
spectrum in female mice. In dogs, we have defined a 
dose of rapamycin that is well tolerated, and initial 
results are consistent with improvements in age-
associated cardiac function similar to those observed in 
rapamycin-treated mice. These data suggest that a 
transient treatment with rapamycin may yield robust 
health benefits in mice, dogs, and perhaps humans. 
 
Stephen Spindler (University of California, Riverside) 
presented “Flies, mice and humans, and the search for 
longevity therapeutics”. 
  
James Mitchell (Harvard T.H. Chan School of Public 
Health) reported “Increased endogenous hydrogen 
sulfide as a conserved mechanism of longevity 
extension”. 
  
Maxim Skulachev (Mosсow State University) 
presented “Development of mitochondrially-targeted 
geroprotectors: from the molecular design to clinical 
trials and marketing strategy”. Research and 
development of geroprotectors is always challenging 
when the project passes from theoretical and laboratory 
work to routine drug development (preclinical and 
clinical trials and medical authority approvals). In this 
talk, we present an example of an anti-ageing RnD 
project aimed on creation of geroprotector drugs on the 
basis of rechargeable mitochonrially-targeted 
antioxidants. Our strategy is to get the potential gero-
protector approved as a drug against a certain age-
related disease, and then to expand the list of indications 
for this pharmaceutical to other traits of ageing. We 
synthesized a series of novel organic compounds, 
namely, cationic, membrane-permeable derivatives of 
plastoquinone. Preclinical studies gave very promising 
results in several animal models of age-related diseases, 
including eye-diseases, neurodegeration and inflam-
mation.  Our first pharmaceutical was designed for local 
administration (in the form of eye-drops) to speed up 
the process of clinical development and to get the 
clinical data faster. At the current stage of the project 
our first drug Visomitin (Rx eye drops with antioxidant 
SkQ1 helping in such age-related diseases as dry eye 
syndrome and cataract) has been approved and 
marketed in Russia and successfully passed phase II 
clinical trials in US.  Systemic oral form of SkQ1 has 
entered clinical trials in Russia and completed 
preclinical program in US and Canada. We consider our 
project to be a valuable attempt to slow down human 
aging by a mitochondrial approach. 
  
Sibylle Jager (L’Oreal) presented “Longevity 
compounds for skin anti-aging: promising strategy or 
false hope”. 
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Andrey Voronkov (Moscow Institute of Physics and 
Technology) presented “Polypharmacological 
geroprotectors for healthy longevity”. In modern drug 
discovery, the concept of polypharmacology has 
attracted substantial attention. In this concept one multi-
targeting drug, or drugs combination is used for 
targeting of several, complementary biotargets, which 
can result in synergistic effect. Synergism results from 
increase of the efficiency due to the complex 
interactions between biotargets and networks, regulated 
by them. Synergistic effects can assist the reduction of 
the therapeutic dose and correspondingly reduce the 
side effects.  Therefore multi-targeting represents a very 
prospective direction for the drug discovery, which can 
be used for the treatment of the complex and difficult 
for the treatment diseases, while the side effects of such 
therapies will be reduced in comparison to single-
targeting drugs combinations.  One example of such 
diseases are oncologic diseases without cures. Another 
example of such condition is aging. We are working on 
the universal methods and approaches for design of the 
small molecules, capable to regulate complex biological 
processes, such as aging and cancer, while at the same 
time such therapies will expose organism to minimum 
of the possible side effects. 
  
Alexey Moskalev (Institute of Biology of Komi 
Science Center of Russian Academy of Sciences) 
presented “Geroprotectors study on Drosophila model”. 
To date, more than 200 substances that prolong the life 
of model organisms have been reported in the literature 
(geroprotectors.org). Reducing the cost and improving 
the efficiency with which increasingly large amounts of 
data from model organisms can be applied to humans 
will be critical to progress in the development of human 
geroprotectors. For this purpose, we have to come to an 
agreement what should be considered applicable to 
human geroprotectors. Primary selection criteria for 
potential geroprotector: 
1. Increased lifespan in models or human. The increase 
in lifespan is not always accompanied by positive 
changes in the quality of life, and additional criteria for 
geroprotectors is needed, and discussed below 
2. Amelioration of human aging biomarkers 
(http://ageing-map.org) 
3. Acceptable toxicity 
4. Minimal side effects 
5. Improving health-related quality of life 
Secondary selection criteria for potential geroprotector: 
6. Evolutionary conservatism of target or mechanism of 
action (agingchart.org) 
7. Reproducibility of geroprotective effects on different 
model organisms 
8. Simultaneous influence on several aging-associated 
causes of death in mammals 
9. Increase of stress resistance 
Vladimir Anisimov (N.N. Petrov Research Institute of 
Oncology) presented “Light desynchronosis, cancer and 
aging”. Light-at-night has become an increasing and 
essential part of modern lifestyle and leads to a number 
of health problems, including excess of body mass 
index, cardiovascular diseases, diabetes and cancer. 
Exposure to constant illumination was followed by 
accelerate aging and tumorigenesis in female CBA, 
129/Sv and transgenic HER-2/neu mice. Male and 
female rats were subdivided into 4 groups and kept at 
various light/dark regimens: standard 12:12 light/dark 
(LD); natural lighting of the North-West of Russia 
(NL); constant light (LL), and constant darkness (DD) 
since the age of 25 days until natural death. Exposure to 
NL and LL accelerated estrous function switch-off, 
induced metabolic syndrome and tumors, reduced life 
span rats as compared to the standard LD regimen. 
Melatonin given in nocturnal drinking water prevented 
adverse effect of LL and NL. The LL regimen 
accelerated colon carcinogenesis induced by 1,2-
dimethylhydrazine (DMH) in rats whereas DD or the 
treatment with melatonin alleviated the effect of LL. 
The LL regimen accelerated whereas the DD regimen 
inhibits both mammary carcinogenesis induced by N-
nitrosomethylurea in rats. Nocturnal drinking of 
melatonin increased the mean life span in female CBA, 
SHR, SAMP-1 and transgenic HER-2/neu mice. 
Melatonin inhibited spontaneous or chemically induced 
carcinogenesis in mammary gland, colon, uterine cervix 
and vagina, lung, skin and soft tissues. Gene expression 
profile study in the heart and brain of melatonin-treated 
CBA mice has shown that genes controlling the cell 
cycle, cell/organism defense, protein expression and 
transport are the primary effectors for melatonin. 
Melatonin has also increased the expression of 
mitochondrial genes, which correlate with its ability to 
inhibit free radical processes. Meta-analysis of clinical 
data has shown positive effect of melatonin in treatment 
of cancer patients. Thus, we believe that melatonin may 
be used for prevention of premature aging and cancer 
development. 
 
Mikhail Shaposhnikov, Alexey Moskalev (Institute of 
Biology at Komi Science Center of Russian Academy 
of Sciences) and Peter Fedichev (Gero Ltd., Hong 
Kong) presented "Effect of Sun/klaroid gene deletion on 
lifespan, stress resistance, locomotor activity and 
fertility in Drosophila melanogaster". Accumulation of 
the inner nuclear envelope the Sun1 protein leads to 
severe tissue pathologies with decreased lifespan in 
mice with Hutchinson-Gilford progeria syndrome. 
Progeroid animals that are deficient for Sun1 show 
markedly reduced tissue pathologies and enhanced 
longevity. However, the role of SUN1 in normal aging 
is not clear. Here we studied the effect of Drosophila 
melanogaster klaroid/Sun gene deletion, on lifespan, 
www.aging‐us.com  21  AGING (Albany NY) 
stress resistance (to starvation, paraquat, hyperthermia, 
and ionizing radiation), age dynamics of locomotor 
activity and fecundity. It was found that hetero- and 
homozygous for the klaroid/Sun deletion Drosophila 
melanogaster males and females have increased median 
and maximum lifespan. It was noted that lifespan in 
flies homozygous for studied deletion was longer than 
in heterozygotes flies. The effect of the klaroid/Sun 
deletion on stress resistance depends on the genotype 
and the sex. In males, the klaroid/Sun deletion leads to 
an increase in locomotor activity, while in females there 
were no changes in locomotor activity. The increased 
female fecundity was detected in individuals with the 
mutation in the klaroid/Sun gene for both homo- and 
heterozygote. Thus, the increase in lifespan in 
klaroid/Sun Drosophila melanogaster mutants is not 
accompanied by the negative effects on fecundity, stress 
resistance and locomotor activity. 
  
Accumulation of the inner nuclear envelope the Sun1 
protein leads to severe tissue pathologies with decreased 
lifespan in mice. However, animals that are deficient for 
Sun1 show markedly reduced tissue pathologies and 
enhanced longevity. Here we studied the effect of 
Drosophila melanogaster klaroid/Sun gene deletion, on 
lifespan, stress resistance (to starvation, paraquat, 
hyperthermia, and ionizing radiation), age dynamics of 
locomotor activity and fecundity. It was found that 
hetero- and homozygous for the klaroid/Sun deletion 
Drosophila melanogaster males and females have 
increased median and maximum lifespan. It was noted 
that lifespan in flies homozygous for studied deletion 
was longer than in heterozygotes flies. The effect of the 
klaroid/Sun deletion on stress resistance depends on the 
genotype and the sex. In males, the klaroid/Sun deletion 
leads to an increase in locomotor activity, while in 
females there were no changes in locomotor activity. 
The increased female fecundity was detected in 
individuals with the mutation in the klaroid/Sun gene 
for both homo- and heterozygote. Thus, the increase in 
lifespan in klaroid/Sun Drosophila melanogaster 
mutants is not accompanied by the negative effects on 
fecundity, stress resistance and locomotor activity. 
  
Ekaterina Proshkina with co-authors (Institute of 
Biology of Komi Science Center of Russian Academy 
of Sciences) presented “The influence of the activity of 
DNA damage recognition and repair genes on the 
lifespan of Drosophila melanogaster”. DNA damage is 
commonly occurs in the course of normal metabolic 
processes and accompanied aging. At the same time, a 
number of facts evidenced the relationship between 
DNA repair efficiency and longevity of organisms. In 
the present research authors focused on the 
determination of lifespan by activity of different DNA 
damage recognition and repair genes using the fruit fly 
D. melanogaster as a model object. In the most cases, 
mutations in genes, which encode proteins providing 
DNA damage recognition (ATM and ATR 
homologues), regulation of stress response (p53 and 
Gadd45), DNA excision repair (XPC, XPF, PCNA 
homologues), and double-strand break repair (BLM, 
Rad50, Rad54, XRCC3 homologues), sufficiently 
decreased D. melanogaster lifespan. Thus, dysfunction 
of DNA repair genes impairs organism vitality and 
reduces lifespan. An alternative approach is the 
screening for genes the overexpression of which 
increases the lifespan. Overactivation of DNA repair 
genes encoding enzymes that coordinate the recognition 
of DNA damage (HUS1, CHK2 homologues), base and 
nucleotide excision repair (AP-endonuclease-1, XPF 
and XPC homologues), double-strand break repair 
(BRCA2, XRCC3, KU80 and WRNexo homologues) 
led to both the positive and negative effects on D. 
melanogaster lifespan dependent on driver, stage of 
induction, gender and the role of a gene in the DNA 
repair process. Conditional ubiquitous and constitutive 
neuron-specific overexpression of investigated DNA 
repair genes negatively changed lifespan. Constitutive 
ubiquitous and conditional neuron-specific 
overexpression of genes involved in DNA damage 
recognition and repair mainly prolongs lifespan. Most 
beneficial effects were found out for homologous of 
genes HUS1, CHK2, XPC and XPF, that execute 
regulatory functions and provide the excision repair 
process. At the same time, negative effects of the 
stimulation of DNA repair genes can be associated with 
the absence of appropriate epigenetic regulation and the 
excessive energy expenditure. 
  
Ekaterina Lashmanova and colleagues (Moscow 
Institute of Physics and Technology) presented “The 
effects of novel 2-selenohydantoin derivatives on 
lifespan and stress resistance of nematodes”. Selenium 
is an essential element for human health. It plays an 
important role in thyroid hormone metabolism and 
immune system. It also possesses antitumor effects. 
Furthermore, selenium is present in the enzyme 
glutathione peroxidase, which detoxifies peroxides and 
hydroperoxides, and selenium availability regulates 
enzyme’s activity. Recently, 12 novel 2-
selenohydantoin derivatives were synthetized and their 
antioxidant activity was revealed using electrochemical 
methods (Ivanenkov et al., 2016). The goal of the 
present study was to investigate the effects of these 
compounds on lifespan and stress resistance of 
nematodes. 
 
 The experiments were performed using the wild type 
N2 Caenorhabditis elegans. Nematodes were cultured in 
liquid medium at 20 ºС in 96-well plates. Selenium-
containing compounds were added in final 
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concentrations 100, 10 and 1 µМ on the first day of 
adulthood. Each experiment was performed five times. 
In addition, the effects of these compounds on the 
survival of nematodes under stress conditions was 
studied.  
 
The addition of 2-selenohydantoin derivatives didn’t 
significantly effect resistance of nematodes to oxidative 
stress (100 mM paraquat) and heat shock (33ºC). Eleven 
2-selenohydantoin derivatives out of twelfth did not 
have any significant effects on median and maximum 
lifespan of nematodes or effects were not stable. At the 
same time, one of the studied compounds in 
concentration 1 µМ significantly increased the median 
lifespan of C. elegans by 11%. However, the effects of 
this compound in other concentrations were not 
detected. 
 
These results indicate the prospects of search of 
geroprotectors among 2- selenohydantoin derivatives. 
 
Ilya Solovev, Eugenia Dobrovolskaya with co-authors 
(Institute of Biology of Komi Science Center of Russian 
Academy of Sciences) presented “Effect of neuron-
specific circadian clock gene overexpression on 
Drosophila melanogaster lifespan”. Genes of circadian 
rhythms change their expression during aging of 
different organisms. We analyzed available 
transcriptomic data from different on-line bases and 
compared circadian genes’ expression profile changes 
in animals (Caenorhabditis  elegans, Drosophila 
melanogaster, Mus musculus, Homo sapiens, 
Heterocephalus glaber, Strongylocentrotus purpuratus 
and Balaena mysticetus) showing various aging rates. 
We investigated from the datasets that expression 
profiles of circadian genes in heads of old Drosophila 
melanogaster are almost identical with the profiles in 
young imagos after ingestion of prooxidant, with the 
exception of tim and pp2A-B’ genes. In addition, such 
genes as clk, per, cry, pdp1, vrille, cwo decreased their 
expression levels in normally aging individuals, when 
cyc, tim, bdbt, sgg, pdf showed an increase. These 
findings have led us to an idea of normalizing 
expression profiles of circadian oscillator elements to 
compensate potential aging-associated changes during 
all lifespan. Primarily, we overexpressed clk, per, cry, 
cyc and tim using neuron-specific RU486-inducible 
system, this resulted in the increase of median life 
expectancy (10%) in tim- and cry12-overexpessing 
females. Median lifespan of female fruit flies 
overexpressing per10 was 5.4% longer than in control 
group. Noteworthy, overexpression of clk shortened (-
10%) only female’s lifespan. 4% augmentation of 
median life expectancy was observed for males 
overexpressing per24 and cyc. 
  
Eugenia Dobrovolskaya, Ilya Solovev with co-authors 
(Institute of Biology of Komi Science Center of Russian 
Academy of Sciences) presented “Effects of caloric 
restriction on lifespan of Drosophila melanogaster 
individuals with tissue-specific overexpression of 
circadian clock genes”. The aging process is associated 
with changes in the expression level of various genes. 
Genes forming a system of "biological clock" of the 
body are not an exception, it evidenced by the 
worsening with age in physiological rhythms and 
aperiodizm of sleep and wakefulness cycles in old 
individuals. The molecular clock found in each cell of 
the peripheral tissues of multicellular organisms. A 
main environmental factor connected to the rhythms of 
biological processes is light, with daily and annual 
variations in the light intensity are associated with such 
phenomena as sleep, physical activity, rest, growth, 
reproduction, sexual behavior, moult and migration. 
Most human genes of circadian rhythms are 
evolutionarily conserved and have orthologs in the fruit 
fly Drosophila melanogaster. It was found that adults of 
D. melanogaster show the decrease in gene expression 
of photosensitive protein Cryptochrome with age, while 
its overexpression in old flies slows down the rate of 
aging. On the other hand, fruit flies with mutations in 
the genes of circadian rhythms are characterized by a 
reduced life span. The purpose of this study was to 
investigate wheather caloric restriction affected the life 
span of Drosophila melanogaster with overexpressed 
circadian rhythms' genes (Period, Timeless, Clock, 
Cycle, Cryptochrome). We chose UAS / GAL4 system 
to ensure conditioned (mifepristone-inducible) gene 
overexpression in flies' muscules, fat body and gut. 
Drosophila lines were placed on standard media with 
different caloric values and life span had been being 
observed once a day. The results of this study 
demonstrate the relationship of circadian rhythms' gene 
regulation mechanisms and caloric restriction response 
pathways. 
  
Darya Peregudova with co-authors (Institute of 
Biology of Komi Science Center of Russian Academy 
of Sciences) presented “Chemical (formaldehyde, 
toluene, tcdd) and physical (ionizing radiation) factors 
influence on the physiological and genetic Drosophila 
melanogaster characteristics”. The changes of living 
organisms’ physiological characteristics caused by 
various stressors are based on the cellular and molecular 
alterations. The reason for changes in the gene 
expression may be caused by the direct gene damage 
due to exposure, or activation of different mechanisms 
of an organism’s biological structures damage 
recognition and stress response promotion. The 
actuality of the formaldehyde, toluene, TCDD and 
irradiation low doses effects studying is their 
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widespread occurrence and negative impact on living 
organisms. 
 
The aim of this work was to study changes in 
expression of stress response genes (Hsp70, Mus209 
(PCNA), Mus210 (XPC), Rrp1, Brca2, spn-B, Ku80, 
PARP-1, Gadd45, Wrinkled / Hid, Sod1, Sod2, 
Catalase, MST-1, Cyp4e2), immune response genes 
(Drosomycin, Defensin, Metchnikowin) and genes 
associated with aging (dSir2, FOXO, JNK), caused by 
the exposure to low doses of dioxin (0.822 and 1.644 
µmol/L), toluene (50 and 100 µmol /L), formaldehyde 
(7%, 14%), and irradiation (20 and 40 cGy), and to 
study the attendant changes in physiological 
characteristics (life span, locomotor activity, fertility) in 
Drosophila melanogaster male and female (Canton-S 
wild type strain). As a result of this work, it was showed 
that the above-mentioned impacts cause a significant 
increase in median life span of Drosophila melanogaster 
wild type strain Canton-S individuals (by 2-4%), there 
were no changes in female fertility, the locomotor 
activity in males was significantly increased. It is also 
have been shown that the biggest part of the studied 
genes increases its expression after exposure to low 
doses of formaldehyde, toluene, dioxin and irradiation. 
 
Nadezhda Zemskaya (Institute of Biology of Komi 
Science Center of Russian Academy of Sciences) with 
co-authors presented “The relationship of lifespan and 
stress resistance of different Drosophila species”. The 
relationship of stress resistance and longevity was 
described based on the results of experiments with 
various lines of certain biological species. As a rule, 
long-lived lines are more resistant to various kinds of 
stress, and short lived mutants of various model 
organisms are hypersensitive to adverse environmental 
factors. Similar links can be determined by comparing 
different species with each other. However, this is a 
lack of most current research in this area, that 
comparisons are made between evolutionarily far-
spaced species (rodents, bats, man, whales), and many 
identified patterns associated with aging may actually 
be only distantly related to the problem. 
 
The aim of this work was to study the differences in 
stress resistance of several species of the Drosophila 
genus, which are significantly different in lifespans. We 
investigated 12 Drosophila species (D. ananassae, D. 
austrosaltans, D. biarmipes, D. erecta, D. kikkawai, D. 
melanogaster, D. pseudoobscura, D. saltans, D. 
simulans, D. virilis, D. willistoni, D. yakuba) provided 
by Dr. V. Gladyshev (Harvard Medical School, USA), 
and estimated their lifespan as well as resistance to 
oxidative stress (20 mM paraquat), hyperthermia (35 
˚C) and starvation. Correlation analysis of stress 
resistance and longevity data was performed. Studied 
Drosophila species demonstrated different reaction to 
stressors. The extremely long lifespan and enhanced 
resistance to all investigated stressors was found for D. 
virilis. Additionally, relatively high survival was shown 
for D. melanogaster under oxidative stress, for D. 
kikkawai and D. pseudoobscura under hyperthermia, for 
D. biarmipes in the starvation condition. Obtained data 
revealed relationship between maximum lifespan and 
stress-resistance of Drosophila species. 
  
Evgeny Rogaev (Vavilov Institute of General Genetics 
RAS) “Aging, Genomics, Alzheimer' Disease”. 
  
Sergey Kozin (Engelhardt Institute of Molecular 
Biology, Russian Academy of Sciences) presented 
“Aged isoform of β-amyloid as biomarker and drug 
target of Alzheimer’s disease”. Alzheimer’s disease 
(AD) is closely associated with ageing. In view of the 
amyloid hypothesis, the key molecular event of AD is a 
structural transition of β-amyloid (Aβ)  from the 
physiologically normal monomer state to soluble 
neurotoxic oligomers accumulating in the form of 
insoluble extracellular aggregates (amyloid plaques) in 
brain tissues. Zinc ions as well as ‘aged’ Aβ species 
present in the plaques are known to play a crucial role 
in triggering pathological conversion of endogenous 
Aβ. Isomerization of Asp7 is the most abundant age-
related spontaneous non-enzymatic modification of Aβ. 
Our in silico, in vitro and in vivo studies have shown 
that Aβ species with isomerized Asp7 (isoAsp7-Aβ) 
significantly differ in their properties from healthy 
(non-modified) Aβ molecules. We have found that 
isoAsp7-Aβ might constitute a nucleation seed  and 
initiate  formation of the neurotoxic zinc-dependent Aβ 
oligomers, thus inducing  development of cerebral 
amyloidosis and other pathological processes 
characteristic of AD. Moreover, the role of the Aβ 
metal-binding domain (the N-terminal region 1-16) as 
the minimal necessary and sufficient pathogenic unit of 
isoAsp7-Aβ has been strongly suggested.  These 
findings allow to link the emergence of isoAsp7-Aβ due 
to Aβ ageing with the onset of age-related pathology, 
and to use isoAsp7-Aβ species as potential biomarkers 
and drug targets of early diagnosis and therapy of AD. 
  
Anatoliy Yashin (Duke University) presented 
“Genetics of Alzheimer’s Disease: Insights for Studying 
Connection among Health, Aging, and Longevity”. A 
number of independent genome-wide association 
studies (GWAS) of Alzheimer’s disease (AD) detected 
highly significant associations of genetic variants from 
APOE and TOMM40 genes with this disorder. 
Epidemiologic studies detected connections of AD with 
other diseases such as cancer, Parkinson disease, type II 
diabetes, CVD, and others. A number of studies link 
AD with presence of viral and bacterial infections (e.g., 
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herpes simplex type 1 virus). Other studies find 
association of AD with processes developing in aging 
brain. The existence of such connections indicates that 
GWAS of AD may also detect genetic variants 
associated with other diseases, and help investigate 
common genetic mechanisms that link AD and related 
pathologies. This may contribute to better 
understanding of the origin of AD and improve 
efficiency of corresponding preventive and treatment 
strategies. We performed GWAS of Alzheimer’s 
disease (AD) using LOADFS data available from 
dbGaP. The analyses showed strong (genome-wide 
significant) genetic signals for SNPs from several genes 
on chromosome 19. These include CTB-129P6.4, CTB-
129P6.7, PVRL2, TOMM40, APOE, APOC1 and 
BCAM. Associations of SNPs from HLA-DQB2, 
LINCO1006, DKFZp779M0652, RNASE11, RP11-
14J7.6, MIR7154 were close to genome-wide 
significance. These results are obtained in joint and 
separate analyses of male and female data. SNPs 
detected in these analyses were also found in studies of 
human longevity (e.g., rs2075650). This SNP is 
downstream gene variant of the PVRL2 characterized as 
“poliovirus receptor-related 2 (herpes virus entry 
mediator B)”. This SNP is also an intron variant of 
TOMM40 gene. We reviewed evidence from other 
studies of AD and its connection with other health 
disorders and compared them with our findings. The 
results of these analyses indicate that development of 
AD involves several genetic pathways that have 
connection to development of other chronic pathologies. 
  
Rosie Freer (Cambridge University) presented “A 
protein homeostasis signature in healthy brains 
recapitulates tissue vulnerability to Alzheimer’s 
disease”. In Alzheimer’s disease, the aggregation of 
amyloid-beta and tau in plaques and tangles spreads 
progressively across brain tissues following a 
characteristic pattern. Over two decades after the 
characterization of the progressive development of this 
disease, the mechanisms that govern the selective 
vulnerability of these tissues remain under debate. 
Using transcriptional analysis of healthy brains, we 
identify an expression signature that predicts – well 
before the onset – the tissue-specific vulnerability to 
disease. We obtain this result by finding a quantitative 
correlation between the histopathological staging of the 
disease and the specific expression patterns of the 
proteins that co-aggregate in plaques and tangles, 
together with those of the protein homeostasis 
components that regulate amyloid-beta and tau. Since 
this expression signature is evident in healthy brains, 
our analysis provides an explanatory link between a 
tissue-specific environmental risk of protein 
aggregation and a corresponding vulnerability to 
Alzheimer’s disease. 
 Natalia Stefanova (Institute of Cytology and Genetics 
of Siberian Branch of Russian Academy of Sciences) 
“Prefrontal cortex transcriptomic indices of sporadic 
Alzheimer's disease in human and in a rat model”. 
Alzheimer’s disease (AD) is the most prevalent 
neurodegenerative disease. We showed that senescence-
accelerated OXYS rats represent a promising model of 
sporadic form of AD with the typical signs of disease: 
degenerative alterations and death of neurons, synaptic 
and mitochondrial dysfunction, hyperphosphorylation 
of the tau protein, accumulation of amyloid β, and the 
formation of amyloid plaques. Here, we aimed to 
compare the gene expression profiles of the prefrontal 
cortex from OXYS rats and Wistar rats as controls to 
identify the molecular mechanisms and the factors 
underlying disease progression. The transcriptome 
analysis was conducted at three stages of the disease 
(pre-symptomatic, symptomatic and progressive stage) 
in OXYS rats, using RNA-Seq technique. We identified 
marked differences in the prefrontal cortex 
transcriptome between the two rat strains already at the 
pre-symptomatic disease stage (> 600 genes), with an 
increasing of gene expression in the symptomatic stage 
(> 900 genes) and at the progressive stage (> 2 000 
genes) in OXYS rats compared with age-matched 
Wistar rats. Gene ontology analysis of the 
transcriptional profile from OXYS rats showed marked 
changes of specific pathways involved in AD molecular 
pathway, as well as in mitochondrial and synaptic 
functions, protein phosphorylation, Са2+ homeostasis, 
hypoxia, immune processes, and apoptosis. Then, we 
compared the gene expression profiles of the prefrontal 
cortex from human AD and OXYS rats.  We 
demonstrated that transcriptional profile changes in the 
cortex as in human AD as well in OXYS rats, primarily 
due to mitochondrial dysfunction, synaptic plasticity 
and Ca2-signaling pathway. This study highlights a set 
of key genes and molecular pathway indices of disease 
which may prove useful in identifying potential disease 
modifiers responsible for the heterogeneity of human 
sporadic form of AD and which may represent valid 
therapeutic targets for ameliorating the disease course in 
humans. 
  
Olga Kovalchuk (University of Lethbridge) presented 
“Chemo brain and aging – is there a link?”. It is 
projected that by 2030 newly diagnosed cancer cases 
will reach 21.7 million worldwide.  The development of 
new chemotherapeutic agents and regimens for cancer 
therapy has led to increasing rates of survival in cancer 
patients and, therefore, it is important to ensure that 
cancer survivors suffer minimal side effects and have 
good life quality. Despite of undisputed benefits, 
chemotherapy causes a wide array of side effects, 
including central nervous system (CNS) toxicity.  
Chemotherapy-induced CNS side effects impact the 
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cognitive domains of attention, memory, processing 
speed, and executive function, causing a condition that 
has been termed chemo brain.  While the molecular and 
cellular mechanisms of chemo brain are not well 
investigated, the frequency and timing of its occurrence 
and their persistence suggest that chemo brain may be 
epigenetic in nature. We analyzed the effects of two 
commonly used cytotoxic chemotherapy drugs—
cyclophosphamide (CPP) and mitomycin C (MMC) - on 
transcriptomic and epigenetic changes in the murine 
prefrontal cortex (PFC) and hippocampal regions. The 
key findings of our study are: (i) chemotherapy altered 
the gene expression profiles in the brain; (ii) MMC 
treatment resulted in accumulation of 8-oxodG, 
decreased global DNA methylation, and increased DNA 
hydroxymethylation in the PFC tissues of female 
animals; and (iii) the majority of the changes induced 
by MMC in the brain tissues resembled those that occur 
during the aging processes. This is the first study that 
suggests a link between chemotherapy-induced chemo 
brain and brain aging, and provides an important 
roadmap for future analysis. 
  
Vasily Popov (Voronezh State University) presented 
“Methylene blue rejuvenates behavior and induces brain 
mitochondria biogenesis in aging mice”. Age-related 
brain dysfunctions are believed to be associated with 
deregulation of mitochondria functions increasing risks 
to develop neurodegenerative diseases (ND). Recently, 
mitochondria –targeting drug methylene blue has been 
drawing considerable interest as a potential treatment 
for ND. Despite well studied effects of MB at the level 
of isolated mitochondria and cells in several ND 
models, its effects on the functioning of non-diseased 
brain remains unexplored. We have compared the effect 
of per oral MB treatment on the behavior, mitochondria 
reactive oxygen species generation, and gene expression 
in adult and aged mice. We found that 15 month old 
mice manifested a decrease in physical endurance, 
spontaneous locomotor activity, and exploration 
concomitant with an increase in anxiety-related 
behavior, as compared to 7 month old mice. A 60 day 
MB treatment slow down these changes in 15 month old 
mice. There was no significant body weight change, 
oxygen consumption rate and RQ index in either adult 
or aged MB-treated mice. MB significantly increased 
the rate of ROS production in isolated brain 
mitochondria. The expression of several genes relevant 
to mitochondria biogenesis, bioenergetics, and 
antioxidant defense (NRF1, MTCOX1, TFAM, SOD2) 
was greatly suppressed in aged mice; it was restored by 
MB treatment. We hypothesize that the effects of MB 
may be mediated by its ability to increase H2O2 
production in brain mitochondria, which in turn 
activates Nrf2/ARE signaling pathway and 
mitochondria biogenesis. 
Khusru Asadullah (Editor in Chief of Advances in 
Precision Medicine) presented “Trends in translation 
medicine: the value of external innovation”. 
Collaborations between academic institutions and the 
diagnostics/pharmaceutical industry are increasingly 
being initiated and executed. It’s assumed that these 
relationships could help to improve research and 
development productivity in industry, as well as enable 
academic institutions to better exploit the translational 
potential of their research. Identification and validation 
of targets and biomarkers, key elements of successful 
drug discovery, are challenging. Unfortunately, 
according published data are frequently irreproducible. 
Thus, we must not rely on published data only. 
Extensive joined efforts of multiple partners seem 
crucial to foster progress. Different models are used and 
required for different stages of the drug discovery and 
development process as well as for different kinds of 
targets and biomarkers. 
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